Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
ACA, acid, Ahura, Anivive, Annex, anniversary, antibiotic, antifungal, antimyeloma, antitumor, APA, APC, arthralgia, Article, ASEAN, Aspect, ASUNo, back, bankruptcy, Barr, BCMA, BESP, bill, billion, biopsy, biotech, bipartisan, blinded, Bluebird, borne, Brexit, bribery, burden, censored, Century, chamber, chaperone, check, ChemotherapyIn, China, Choi, cited, clear, climate, clinician, closest, codified, compensatory, composed, constipation, countermeasure, counterparty, CRC, criterion, CSR, CTA, daily, Deeper, dehydrogenase, deliverable, dictate, digit, Digital, DSCSA, dysgeusia, dysregulated, EHA, electorate, element, eltanexor, endorsement, entail, Epstein, error, ethical, exploit, Falvey, FDARA, Fidelity, flow, forward, France, halted, harmonized, hazard, Hong, House, HR, hybrid, hypermethylation, ICRR, IDHIFA, IMPD, implicit, incomplete, incremental, indefinitely, Infinity, infrequent, inhibitory, inRecently, insolvency, Inspector, interaction, intracranial, inventory, IRC, isocitrate, Italy, Japan, Johnson, jointly, judgment, Kingdom, Kong, Korea, leaving, Leishmania, leukopenia, levied, licensor, Lisbon, locoregional, MA, mandate, Master, mCRPC, melflufen, membrane, MIT, MMRFmid, monocolonal, NDMM, neutrality, niacin, nicotinic, ninety, noncompliance, nonspecific, notification, Notwithstanding, offshore, OMB, Ono, onset, orin, overseen, page, PARP, passed, pathology, PCAOB, permissible, PHSA, Polymerase, potency, problematic, rational, Reauthorization, reauthorize, RecurrentENDOmetrial, referendum, RefractoryAML, regenerative, regime, remeasurement, remediation, repatriated, Republic, resensitize, retreatment, Rett, revaluation, revalue, Revlimid®in, routine, rulemaking, sabotage, Scholar, Seley, Senate, session, shelf, shortage, shrinkage, shut, SIENDO, signature, silenced, sixteen, SKd, skinny, Sloan, SmPC, social, South, Southeast, Spain, spur, SRd, stalled, standalone, stay, stratified, stricter, strongly, suit, survivin, symptomatic, Taiwan, TCJA, Territory, threat, tiered, TJCA, toxin, TPE, Trump, Trypanosoma, UK, unambiguously, unclear, uncommon, undelivered, undergraduate, undermine, unfair, untreated, Velcade®and, Velcade®demonstrated, vendotin, voucher, VSOE, wider, willingly, withRelapsed, Yescarta
Removed:
ABC, activated, actively, activityin, adenocarcinoma, Affordability, Andersen, andin, antiviral, arabinoside, ArQule, Arthur, assembly, ASU, avian, azacytidine, blast, Blockade, blocked, blunt, Boehringer, buyer, bytransiently, cervical, Chicago, closed, Coley, collectability, CombinatoRx, compartment, concomitant, consisting, contrast, converted, counteract, create, cytosine, Daiichi, dampening, defense, designing, dex, direction, disrupted, dysfunction, enhancing, exceeding, exerted, experiencing, factorkB, falsifying, forfeiture, greatest, grow, HIV, Holy, hydroxyurea, immunoblastic, improperly, inappropriately, influenza, Ingelheim, instrumental, intact, investigate, Kite, left, lung, Merck, mice, Millipore, MMA, Modernization, monetization, multifaceted, multitude, mutant, myeloid, naturally, network, neuraminidase, neuronal, Northeastern, objectively, ofin, oncogenic, oralSelective, orSINE, oseltamivir, parenterally, pegylated, permanently, positively, potent, PPACA, progressing, provisional, quizartinib, rat, receptor, refund, relapsing, rendered, renovation, responsive, retention, reversed, ribosomal, Sankyo, sCR, screening, Serono, strain, structural, Suffolk, suppression, Tamiflu, TBI, theirreversible, titer, transcriptional, transporter, transporting, trapping, unique, unrestrained, vehicle, vested, vivo, volasertib, vorinistat, vRNP, Western, Zolinza
Filing tables
Filing exhibits
Related press release
Associated KPTI transcripts
KPTI similar filings
Filing view
External links
Exhibit 12.1
STATEMENT REGARDING COMPUTATION OF CONSOLIDATED RATIOS OF EARNINGS TO FIXED CHARGES AND RATIOS OF EARNINGS TO COMBINED FIXED CHARGES AND PREFERRED STOCK DIVIDENDS
Fiscal Year Ended December 31, | ||||||||||||||||||||
2017 | 2016 | 2015 | 2014 | 2013 | ||||||||||||||||
Loss from operations | (128,984 | ) | (110,732 | ) | (119,076 | ) | (75,846 | ) | (33,950 | ) | ||||||||||
add: Fixed charges (see below) | 399 | 383 | 344 | 173 | 58 | |||||||||||||||
|
|
|
|
|
|
|
|
|
| |||||||||||
Pre-tax loss from continuing operations plus fixed charges | (128,585 | ) | (110,349 | ) | (118,732 | ) | (75,673 | ) | (33,892 | ) | ||||||||||
Fixed charges: | ||||||||||||||||||||
Interest expense on indebtedness | — | — | — | — | — | |||||||||||||||
Interest expense on portion of rent expense representative of interest | 399 | 383 | 344 | 173 | 58 | |||||||||||||||
|
|
|
|
|
|
|
|
|
| |||||||||||
Total fixed charges | 399 | 383 | 344 | 173 | 58 | |||||||||||||||
|
|
|
|
|
|
|
|
|
| |||||||||||
Ratio of earnings to fixed charges | — | — | — | — | — | |||||||||||||||
|
|
|
|
|
|
|
|
|
| |||||||||||
Deficiency of earnings available to cover fixed charges | (128,984 | ) | (110,732 | ) | (119,076 | ) | (75,846 | ) | (33,950 | ) | ||||||||||
|
|
|
|
|
|
|
|
|
|
$ in thousands